Watch for these signs
After 1 year of this treatment, a cessation of further gain was observed for the first time, with BMI decreasing to 50.3 kg/m 2 - a level that remained elevated but suggested a halt in disease progression
But, like other medications in the market, the pricing of GLP-1 agonist medicationsregardless of administration methodmay vary depending on health insurance coverage and other factors such as supply and demand. Will GLP-1 drops really take off
65,66 A network meta-analysis ranked SEMA 0.4 mg first in the resolution of MASH among alternative treatments [surface under the cumulative ranking (SUCRA) = 0.89], higher than liraglutide (SUCRA = 0.84) and resmetirom (SUCRA = 0.44)
Some patients may notice changes in appetite, meal size, blood sugar response, or weight over time
Understanding these can help patients make informed decisions when exploring their options, particularly in the private sector where pricing is less standardised
